Anthropic 发布了一份技术报告，详细介绍了其 Claude 模型如何用于设计新型蛋白质结合物，这是药物开发中的关键一步。该 AI 模型成功为 15 个目标中的 14 个设计了结合物，成功率在 22% 到 35% 之间，显著优于行业通常 10-15% 的成功率。这些设计由 Adaptyv Bio 和 Twist Bioscience 独立构建和测试，验证了 Claude 在这一复杂科学领域的能力。Anthropic 还宣布计划推出一项计划，允许科学家使用其最强大的模型（包括 Opus 5）进行生命科学研究。 AI
影响 展示了 AI 在复杂科学研究中日益增长的能力，有可能加速药物发现流程。
排序理由 研究出版物，详细介绍了 AI 模型在科学领域的 [能力]。
AI 生成摘要 · Google Gemini · 来自 6 个来源。 我们如何撰写摘要 →
We're also publishing a technical report: https://t.co/Ltcqemzn5Z And open-sourcing our prompts and data here: https://t.co/OZXVQWSie2
For more on how Claude ran this experiment and the full results, see our blog: https://t.co/48COrpUcJn
One of our highest priorities remains launching an access program for scientists to use our most capable models. We expect to share more on this soon. Opus 5 remains our most capable model available for life science research.
Importantly, protein binders are not drugs. Designing a high-affinity binder is just the first step in the process of developing a drug-like molecule. Even designing a drug itself is just one phase out of the many required to establish that a drug is safe and effective before
Designing a binder is an easier process than designing a drug, but it’s a useful proxy. The typical success rate in the field today is between 10% and 15%. Between 22% and 35% of Claude's designs bound successfully, depending on the setup. Some of its strongest designs bound htt…
Many drugs work by binding to a specific target in the body and blocking or changing what it does. An important first step in the drug development process is designing a molecule that can bind tightly to its target. Traditionally, that's meant weeks or months of expert work per h…